RU2017100445A - Лечение лимфом - Google Patents

Лечение лимфом Download PDF

Info

Publication number
RU2017100445A
RU2017100445A RU2017100445A RU2017100445A RU2017100445A RU 2017100445 A RU2017100445 A RU 2017100445A RU 2017100445 A RU2017100445 A RU 2017100445A RU 2017100445 A RU2017100445 A RU 2017100445A RU 2017100445 A RU2017100445 A RU 2017100445A
Authority
RU
Russia
Prior art keywords
antibodies
mammal
lymphoma
composition
complexes
Prior art date
Application number
RU2017100445A
Other languages
English (en)
Other versions
RU2708332C2 (ru
RU2017100445A3 (ru
Inventor
Светомир Н. МАРКОВИЧ
Уэнди К. НЕВАЛА
Original Assignee
Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч filed Critical Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч
Publication of RU2017100445A publication Critical patent/RU2017100445A/ru
Publication of RU2017100445A3 publication Critical patent/RU2017100445A3/ru
Application granted granted Critical
Publication of RU2708332C2 publication Critical patent/RU2708332C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (15)

1. Способ лечения млекопитающего, имеющего лимфому, при этом указанный способ включает введение указанному млекопитающему композиции, содержащей наночастицы, имеющие в своем составе альбумин и паклитаксел, образующий комплекс с антителами к полипептидам CD20 в условиях, в которых увеличивается продолжительность жизни без прогрессирования заболевания.
2. Способ по п. 1, в котором указанным млекопитающим является человек.
3. Способ по п. 1, в котором указанной лимфомой является ходжкинская лимфома.
4. Способ по п. 1, в котором указанная композиция содержит Ритуксимаб, образующий комплекс с указанными наночастицами.
5. Способ по п. 1, в котором указанная композиция содержит алкилирующий агент, образующий комплекс с указанными наночастицами.
6. Способ по п. 1, в котором указанными антителами к полипептидам CD20 являются гуманизированные антитела или химерные антитела.
7. Способ по п. 1, в котором указанная выживаемость без прогрессирования заболевания повышается на 15 процентов или на 25 процентов или на 50 процентов или на 75 процентов или на 100 процентов.
8. Способ лечения млекопитающего, имеющего лимфому, при этом указанный способ включает введение указанному млекопитающему композиции, содержащей комплексы альбуминсодержащих наночастиц/антител, при этом средний диаметр указанных комплексов составляет между 0,1 и 0,9 мкм, и при этом указанными антителами являются антитела к CD20.
9. Способ по п. 8, в котором указанным млекопитающим является человек, а указанной лимфомой является новообразование из зрелых В-клеток или новообразование из зрелых Т-клеток или ходжкинская лимфома.
10. Способ по п. 8, в котором указанными комплексами альбуминсодержащих наночастиц/антител являются комплексы альбуминсвязанного паклитаксела/Ритуксимаба.
11. Способ по п. 8, в котором указанная композиция или указанные комплексы альбуминсодержащих наночастиц/антител содержат алкилирующий агент или противовоспалительный агент.
12. Способ по п. 8, в котором указанными антителами к полипептидам CD20 являются гуманизированные антитела или химерные антитела.
13. Способ по п. 8, в котором указанное введение указанной композиции происходит в условиях, в которых среднее время прогрессирования для популяции млекопитающих с указанной лимфомой составляет по меньшей мере 150 дней или по меньшей мере 165 дней или по меньшей мере 170 дней.
14. Способ лечения млекопитающего, имеющего лимфому, при этом указанный способ включает введение указанному млекопитающему композиции, содержащей комплексы альбуминсодержащих наночастиц/антител, при этом средний диаметр по меньшей мере 5 процентов указанных комплексов указанной композиции составляет между 0,1 и 0,9 мкм, и при этом указанными антителами являются антитела к CD20.
15. Способ лечения млекопитающего, имеющего лимфому, при этом указанный способ включает введение указанному млекопитающему композиции, содержащей комплексы альбуминсодержащих наночастиц/антител, при этом средний диаметр по меньшей мере 5 процентов указанных комплексов указанной композиции составляет между 0,1 и 0,9 мкм, и при этом указанными антителами являются антитела к CD20, а не ритуксимаб.
RU2017100445A 2014-06-13 2015-06-12 Лечение лимфом RU2708332C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462012190P 2014-06-13 2014-06-13
US62/012,190 2014-06-13
PCT/US2015/035505 WO2015191969A1 (en) 2014-06-13 2015-06-12 Treating lymphomas

Publications (3)

Publication Number Publication Date
RU2017100445A true RU2017100445A (ru) 2018-07-16
RU2017100445A3 RU2017100445A3 (ru) 2019-01-28
RU2708332C2 RU2708332C2 (ru) 2019-12-06

Family

ID=54834378

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017100445A RU2708332C2 (ru) 2014-06-13 2015-06-12 Лечение лимфом

Country Status (12)

Country Link
US (2) US20160250351A1 (ru)
EP (1) EP3154586B1 (ru)
JP (1) JP6695286B2 (ru)
KR (1) KR102450563B1 (ru)
CN (2) CN113318239A (ru)
AU (2) AU2015274408A1 (ru)
BR (1) BR112016029123A2 (ru)
CA (1) CA2950926A1 (ru)
IL (1) IL249454B (ru)
MX (2) MX2016016369A (ru)
RU (1) RU2708332C2 (ru)
WO (1) WO2015191969A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
US10213513B2 (en) 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
AU2017217881B2 (en) * 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017165440A1 (en) * 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
WO2018027205A1 (en) * 2016-08-05 2018-02-08 Mayo Foundation For Medical Education And Research Modified antibody-albumin nanoparticle complexes for cancer treatment
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
JP2019526579A (ja) * 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｔ細胞癌を標的とする為の方法及び組成物
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
EP3510048A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Methods of treating pd-l1 expressing cancer
CN109890422A (zh) * 2016-09-06 2019-06-14 梅约医学教育与研究基金会 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法
MA46474A (fr) * 2016-10-10 2019-08-14 Abraxis Bioscience Llc Formulations nanoparticulaires et leurs procédés de production et d'utilisation
US11531030B2 (en) 2017-04-21 2022-12-20 Mayo Foundation For Medical Education And Research Polypeptide-antibody complexes and uses thereof
US20210023233A1 (en) * 2018-02-06 2021-01-28 Mayo Foundation For Medical Education And Research Antibody-peptide complexes and uses thereof
JP2023539369A (ja) 2020-09-02 2023-09-13 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 抗体－ナノ粒子複合体、ならびにその作製および使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
EP1755653B1 (en) * 2004-05-14 2014-12-31 Abraxis BioScience, LLC Treatment methods utilizing albumin-binding proteins as targets
JP2008510466A (ja) * 2004-08-19 2008-04-10 ジェネンテック・インコーポレーテッド エフェクター機能が変更しているポリペプチド変異体
US20100112077A1 (en) * 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
BRPI0718585A2 (pt) 2006-11-07 2014-03-11 Dow Agrosciences Llc Formulação de técnica de aniquilação de macho (mat), de liberação controlada, pulverizável e método de controle de inseto
US8345535B2 (en) * 2009-07-13 2013-01-01 Lg Electronics Inc. Method and apparatus for generating ranging preamble code in wireless communication system
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011066374A2 (en) * 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
CN105001334A (zh) * 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
US20130281376A1 (en) * 2010-10-08 2013-10-24 Abraxis Bioscience, Llc Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer
EP2643016A2 (en) * 2010-11-23 2013-10-02 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
US9427477B2 (en) * 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
WO2014055415A1 (en) * 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments

Also Published As

Publication number Publication date
EP3154586A1 (en) 2017-04-19
CN106573051A (zh) 2017-04-19
CA2950926A1 (en) 2015-12-17
AU2021200489A1 (en) 2021-02-25
AU2015274408A1 (en) 2017-01-12
JP2017517556A (ja) 2017-06-29
KR102450563B1 (ko) 2022-10-07
IL249454A0 (en) 2017-02-28
BR112016029123A2 (pt) 2017-08-22
JP6695286B2 (ja) 2020-05-20
EP3154586B1 (en) 2020-05-27
US20160250351A1 (en) 2016-09-01
MX2021002900A (es) 2021-06-08
IL249454B (en) 2021-04-29
KR20170085955A (ko) 2017-07-25
WO2015191969A1 (en) 2015-12-17
CN113318239A (zh) 2021-08-31
RU2708332C2 (ru) 2019-12-06
US20170216453A1 (en) 2017-08-03
MX2016016369A (es) 2017-10-12
CN106573051B (zh) 2021-07-13
EP3154586A4 (en) 2018-01-10
RU2017100445A3 (ru) 2019-01-28

Similar Documents

Publication Publication Date Title
RU2017100445A (ru) Лечение лимфом
JP2017517556A5 (ru)
EA202091587A1 (ru) Анти-tigit антитела и их применение в качестве терапевтических и диагностических средств
MY171135A (en) Antibodies specific for tgf-beta
EA201590671A1 (ru) Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
FI3083694T3 (fi) Kaninisoituja hiiren anti-koira-pd-1 -vasta-aineita
PE20161217A1 (es) Anticuerpos anti-cd3 y metodos de uso
EA201501063A1 (ru) СВЯЗЫВАЮЩИЕСЯ С ЧЕЛОВЕЧЕСКИМ FcRn МОДИФИЦИРОВАННЫЕ АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2014523907A5 (ru)
RU2019114963A (ru) Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
AR070461A1 (es) Metodos y sistemas para tratar trastornos de proliferacion celular usando terapia fotoespectral mejorada con plasmonicos (pepst) y fototerapia mejorada con excitones plasmones (epep). composiciones.
JP2016500251A5 (ru)
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
CL2017000050A1 (es) Terapia de combinación para el cáncer
AR101740A1 (es) Terapia de combinación y composiciones
AR096184A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpos para cd22-fármaco
PH12015502469A1 (en) Fcrn-binding abolished anti-igf-ir antibodies and their use in the treatment of vascular eye diseases
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
EA201690321A1 (ru) Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей
BR112013032456A2 (pt) anticorpo anti-cxcr4 com funções efetuadoras e seu uso para o tratamento de câncer
EA201892525A1 (ru) Конструкции днк-антител для применения против pseudomonas aeruginosa
EA201791138A1 (ru) Фармацевтическая композиция, ее приготовление и применения
JP2013536236A5 (ru)
RU2014117952A (ru) Антитела против sema4a человека, используемые для лечения заболевания